A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip
Primary Purpose
Pain, Activities of Daily Living, Quality of Life
Status
Completed
Phase
Phase 3
Locations
Denmark
Study Type
Interventional
Intervention
Rose-hip powder capsules
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Pain focused on measuring Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Men and women aged 40 + years
- Osteoarthritis symptoms with duration of more than 6 months
- One WOMAC-pain visual analogue scale score (VAS score) there are at least 35 mm at rest
- Subjective morning joint stiffness
- Clinical symptoms of arthritis diagnosed by the ACR (American College Rheumatology) criteria
Exclusion Criteria:
- Patients who have been treated with rose hip extracts or powder within 3 months before screening.
- Patients who have been treated with ginger, avocado or soybean extracts or powder within 3 months before screening
- Patients on steroids, TNFalpha or DMARD prior to trial.
- Patients receiving irregular medical treatment for osteoarthritis.
- Patients suffering from other joint diseases other than osteoarthritis.
- Patients who abuse alcohol
- Patients with a current psychiatric illness, drug and / or alcohol abuse
- Patients with known allergy to rose hips
- Presence of other clinically significant medical conditions
- Patients scheduled for joint or major surgery during the trial.
- Patients participating in another clinical trial, or have participated in another clinical trial within 3 months before this study.
- Patients with known compliance problems or who are uncooperative.
- Pregnant or lactating women.
Sites / Locations
- INCUBA Science Park - Skejby
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo
Rose-hip powder
Arm Description
Daily treatment with placebo
Daily treatment with Rose-hip powder
Outcomes
Primary Outcome Measures
difference in the effect by using WOMAC-pain score.
The effect of treatment within each of the two groups (Rose hip powder and placebo) measured by using the differences in WOMAC-pain scores at 3 months of treatment between active treatment and placebo group, and between baseline and 3 months.
difference in the effect by using WOMAC-ADL score
The effect of treatment within each of the two groups (Rose hip powder and placebo) measured by using the differences in WOMAC-ADL (Activities of Daily Living) scores at 3 months of treatment between active treatment and placebo group, and between baseline and 3 months.
Secondary Outcome Measures
Quality of life
Effects on QoL (SF-12 questionnaire and diaries) after 6 weeks and 12 weeks treatment, both groups compared to baseline, and the effects in the active group compared with the placebo group on QoL (SF-12 questionnaire and diaries) after 6 weeks and 12 weeks treatment.
Difference in the effect by using WOMAC-pain score
The effect of treatment within each of the two groups (Rose hip powder and placebo) measured by using the differences in WOMAC-pain scores at 6 weeks of treatment by compaing baseline to week 6, and the effects in the active group compared with the placebo group at 6 weeks
Patient assessment of the disease
Patient's assessment of the severity of the disease state is (PGAD)after 6 weeks and 12 weeks compareded to baseline and the effects in the active group compared with the placebo group at 6 and 12 weeks treatment
Safety Issue?: (FDAAA) No
difference in the effect by using WOMAC-ADL (Activities of Daily Living)score
The effect of treatment within each of the two groups (Rose hip powder and placebo) measured by using the differences in WOMAC-ADL scores at 6 weeks of treatment by compaing baseline to week 6, and the effects in the active group compared with the placebo group at 6 weeks
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01459939
Brief Title
A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip
Official Title
A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip
Study Type
Interventional
2. Study Status
Record Verification Date
June 2012
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
May 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hyben Vital ApS
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The trial is an investigator-initiated, double-blind, randomized, placebo-controlled phase III study.
After the patient has receiving information about the study and after given written informed consent, the patient will be screened. All patients are randomized to receive standardized rose hip powder or matching placebo for 3 weeks followed by half the dose standardized rose hip (or placebo) for the remaining 12 weeks of the study.
The patient's medical history and demographic information will be recorded. The patient will then be asked questions in accordance to the study questionnaires, and they will also be asked to complete questionnaires regarding quality of life - and finally they be instructed on how to complete the diary.
Investigator or study nurse will take telephone contact with the subject after 3 and 6 weeks of treatment, subjects will be asked about how things are going and to remember to take the capsules and whether they have completed the diary.
The contact taken after 6 weeks by phone is mainly to guide the subject on how complete the questionnaires including VAS scales.
The last patient visit will take place after 12 weeks. Any side effects will be reported to and reviewed with HybenVital ApS in collaboration with medical experts.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Activities of Daily Living, Quality of Life
Keywords
Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Daily treatment with placebo
Arm Title
Rose-hip powder
Arm Type
Active Comparator
Arm Description
Daily treatment with Rose-hip powder
Intervention Type
Dietary Supplement
Intervention Name(s)
Rose-hip powder capsules
Intervention Description
5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
Primary Outcome Measure Information:
Title
difference in the effect by using WOMAC-pain score.
Description
The effect of treatment within each of the two groups (Rose hip powder and placebo) measured by using the differences in WOMAC-pain scores at 3 months of treatment between active treatment and placebo group, and between baseline and 3 months.
Time Frame
12 weeks
Title
difference in the effect by using WOMAC-ADL score
Description
The effect of treatment within each of the two groups (Rose hip powder and placebo) measured by using the differences in WOMAC-ADL (Activities of Daily Living) scores at 3 months of treatment between active treatment and placebo group, and between baseline and 3 months.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Quality of life
Description
Effects on QoL (SF-12 questionnaire and diaries) after 6 weeks and 12 weeks treatment, both groups compared to baseline, and the effects in the active group compared with the placebo group on QoL (SF-12 questionnaire and diaries) after 6 weeks and 12 weeks treatment.
Time Frame
12 weeks
Title
Difference in the effect by using WOMAC-pain score
Description
The effect of treatment within each of the two groups (Rose hip powder and placebo) measured by using the differences in WOMAC-pain scores at 6 weeks of treatment by compaing baseline to week 6, and the effects in the active group compared with the placebo group at 6 weeks
Time Frame
6 weeks
Title
Patient assessment of the disease
Description
Patient's assessment of the severity of the disease state is (PGAD)after 6 weeks and 12 weeks compareded to baseline and the effects in the active group compared with the placebo group at 6 and 12 weeks treatment
Safety Issue?: (FDAAA) No
Time Frame
12 weeks
Title
difference in the effect by using WOMAC-ADL (Activities of Daily Living)score
Description
The effect of treatment within each of the two groups (Rose hip powder and placebo) measured by using the differences in WOMAC-ADL scores at 6 weeks of treatment by compaing baseline to week 6, and the effects in the active group compared with the placebo group at 6 weeks
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men and women aged 40 + years
Osteoarthritis symptoms with duration of more than 6 months
One WOMAC-pain visual analogue scale score (VAS score) there are at least 35 mm at rest
Subjective morning joint stiffness
Clinical symptoms of arthritis diagnosed by the ACR (American College Rheumatology) criteria
Exclusion Criteria:
Patients who have been treated with rose hip extracts or powder within 3 months before screening.
Patients who have been treated with ginger, avocado or soybean extracts or powder within 3 months before screening
Patients on steroids, TNFalpha or DMARD prior to trial.
Patients receiving irregular medical treatment for osteoarthritis.
Patients suffering from other joint diseases other than osteoarthritis.
Patients who abuse alcohol
Patients with a current psychiatric illness, drug and / or alcohol abuse
Patients with known allergy to rose hips
Presence of other clinically significant medical conditions
Patients scheduled for joint or major surgery during the trial.
Patients participating in another clinical trial, or have participated in another clinical trial within 3 months before this study.
Patients with known compliance problems or who are uncooperative.
Pregnant or lactating women.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank Pedersen, Dr
Organizational Affiliation
Aarhus University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
INCUBA Science Park - Skejby
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip
We'll reach out to this number within 24 hrs